GINKGO BIOWORKS HOLDINGS
NYSE: DNA (Ginkgo Bioworks Holdings, Inc.)
Last update: 7 hours ago10.08
1.34 (15.33%)
| Previous Close | 8.74 |
| Open | 8.46 |
| Volume | 1,568,396 |
| Avg. Volume (3M) | 1,192,359 |
| Market Cap | 579,387,328 |
| Price / Sales | 2.73 |
| Price / Book | 0.780 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2024 |
| Profit Margin | -298.78% |
| Operating Margin (TTM) | -58.68% |
| Diluted EPS (TTM) | -12.89 |
| Quarterly Revenue Growth (YOY) | 60.60% |
| Total Debt/Equity (MRQ) | 55.84% |
| Current Ratio (MRQ) | 5.79 |
| Operating Cash Flow (TTM) | -334.98 M |
| Levered Free Cash Flow (TTM) | -317.24 M |
| Return on Assets (TTM) | -20.92% |
| Return on Equity (TTM) | -63.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 0.70 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.15% |
| % Held by Institutions | 68.55% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Anchorage Capital Group, L.L.C. | 30 Sep 2024 | 1,746,363 |
| Opaleye Management Inc. | 30 Sep 2024 | 820,202 |
| Sb Investment Advisers (Uk) Ltd | 30 Sep 2024 | 610,729 |
| Meteora Capital, Llc | 30 Sep 2024 | 509,952 |
| Erste Asset Management Gmbh | 30 Sep 2024 | 500,000 |
| Glenview Capital Management, Llc | 30 Sep 2024 | 474,998 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| SLOAN HARRY | 10.70 | - | 235,780 | 2,522,846 |
| Aggregate Net Quantity | 235,780 | |||
| Aggregate Net Value ($) | 2,522,846 | |||
| Aggregate Avg. Buy ($) | 10.70 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SLOAN HARRY | Director | 11 Dec 2024 | Acquired (+) | 235,780 | 10.70 | 2,522,846 |
| Date | Type | Details |
|---|---|---|
| 17 Dec 2024 | Announcement | Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program |
| 12 Nov 2024 | Announcement | Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing |
| 12 Nov 2024 | Announcement | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results |
| 05 Nov 2024 | Announcement | Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation |
| 24 Sep 2024 | Announcement | NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |